MS LifeLines® is an educational patient support service for people living with MS and their families and is sponsored by EMD Serono, Inc.
Through MS LifeLines, patients have access to individualized support and educational resources to help them make the most of their MAVENCLAD treatment. MS-certified nurses are available to patients. Tell your patients to visit MAVENCLAD.com/support or call 1-877-447-3243 to learn more about MS LifeLines.
MAVENCLAD has formulary coverage across a range of plans, including private and government insurance.
Field Patient Services Manager
MS LifeLines Patient Support Specialist
MS LifeLines Field Nurse Educator
MS LifeLines Support Center Nurse
For more information on the MS LifeLines Pro portal and other patient support options, via Getting Started with MAVENCLAD.
For eligible commercially insured patients who have been prescribed MAVENCLAD, MS LifeLines offers a co-pay assistance program that could reduce their out-of-pocket costs (including co-pays and deductibles) to as little as $0.
MS LifeLines also offers other assistance programs, including free medication to eligible patients to help ensure appropriate patients have access to MAVENCLAD.
Tell your MAVENCLAD patients that they can call MS LifeLines at 1-877-447-3243 to determine if they are eligible for an MS LifeLines financial assistance program.
WARNING: MALIGNANCIES and RISK OF TERATOGENICITY
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
Adverse Reactions: The most common adverse reactions with an incidence of >20% for MAVENCLAD are upper respiratory tract infection, headache, and lymphopenia.
Drug Interactions/Concomitant Medication: Concomitant use of MAVENCLAD with immunosuppressive or myelosuppressive drugs and some immunomodulatory drugs (e.g., interferon beta) is not recommended and may increase the risk of adverse reactions. Acute short-term therapy with corticosteroids can be administered.
Avoid concomitant use of certain antiviral and antiretroviral drugs. Avoid concomitant use of BCRP or ENT/CNT inhibitors as they may alter bioavailability of MAVENCLAD.
Use in Specific Populations: Studies have not been performed in pediatric or elderly patients, pregnant or breastfeeding women. Use in patients with moderate to severe renal or hepatic impairment is not recommended.
Please see the full Prescribing Information, including boxed WARNING for additional information.
MAVENCLAD® (cladribine) tablets is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, use of MAVENCLAD is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS.
Limitations of Use: MAVENCLAD is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile.
WARNING: MALIGNANCIES and RISK OF TERATOGENICITY
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
Adverse Reactions: The most common adverse reactions with an incidence of >20% for MAVENCLAD are upper respiratory tract infection, headache, and lymphopenia.
Drug Interactions/Concomitant Medication: Concomitant use of MAVENCLAD with immunosuppressive or myelosuppressive drugs and some immunomodulatory drugs (e.g., interferon beta) is not recommended and may increase the risk of adverse reactions. Acute short-term therapy with corticosteroids can be administered.
Avoid concomitant use of certain antiviral and antiretroviral drugs. Avoid concomitant use of BCRP or ENT/CNT inhibitors as they may alter bioavailability of MAVENCLAD.
Use in Specific Populations: Studies have not been performed in pediatric or elderly patients, pregnant or breastfeeding women. Use in patients with moderate to severe renal or hepatic impairment is not recommended.
Please see the full Prescribing Information, including boxed WARNING for additional information.